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To the Editor,
After reading the review article titled “The emergency
department care of the cannabis and synthetic cannabinoid patient: a narrative review” by Kevin Takakuwa and
Raquel Schears published in the International Journal of
Emergency Medicine (2021 Feb 10;14(1):10), we want to
first congratulate the authors for the successful publication of this article. Additionally, we hope to contribute
some of our findings to further enhance this line of
research.

Introduction
As the legalization of cannabis continues to spread in
North America, it has become increasingly important for
physicians to recognize and treat cannabinoid-related
syndromes. In this secondary analysis of a randomized
controlled trial that studied the effect of topical capsaicin on patients presenting to the emergency department
(ED) with cannabinoid hyperemesis syndrome (CHS), we
describe symptomatology and return visits in patients
suffering from CHS [1].
Results
Our study population consisted of 29 participants with a
mean age of 30 years. Most patients were Black (90%)
and hypertension was the most frequent comorbid condition (28%). All participants experienced nausea and
vomiting. Other reported symptoms included abdominal
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pain (90%), chills (52%), and diarrhea (27%). Abdominal
pain was mild (mean visual analog scale (VAS) 2.7 ± 1.2
cm) compared to nausea (mean VAS 7.3 ±2.5 cm). Sixteen patients accounted for 41 repeat ED visits and 10
hospitalizations for CHS-related symptoms within 6
months.

Discussion
Data indicates that the increased accessibility of cannabis in the USA is associated with an increase in
cannabis-related conditions presenting to the ED [2].
Many of these conditions have only recently been
characterized and a clearer understanding of CHS
symptomatology may improve its accurate recognition
and treatment.
While the majority of published studies of CHS obtain
retrospective data or present small case series, this prospective data provides an accurate assessment of patient
symptoms and high rates of return visits. It also includes
data on a largely Black cohort, whereas most published
literature on CHS is inclusive of White patients. We
present quantified data on the degree of nausea common
among CHS patients and the degree of abdominal pain.
Contrary to prior studies, we found that abdominal pain
severity is overall mild to moderate, especially when
compared to nausea severity [3]. Given these findings, a
focus on antiemetic treatment rather than analgesics appears warranted in the initial management of these
patients.
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Conclusions
In this cohort of CHS patients, it was found that nausea
was a larger concern for patients than abdominal pain
and that repeat encounters for related symptoms were
common. As cannabinoid use becomes more mainstream, physicians in all settings should include CHS in
their differential when faced with GI symptoms.
Abbreviations
CHS: Cannabinoid hyperemesis syndrome; VAS: Visual analog scale;
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